Author:
Zhao Zinan,Zhao Fei,Zhang Yatong,Hu Xin,Li Jianchun,Tian Chao,Jin Pengfei,Liu Deping
Funder
Ministry of Science and Technology of the People's Republic of China
National Key Research and Development Program of China
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference29 articles.
1. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis;Colacci;Can J Diabetes,2021
2. Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment;Storgaard;Basic Clin Paharmacol Toxicol,2016
3. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis;Wallenius;J Lipid Res,2022
4. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy;Palmer;Clin J Am Soc Nephrol,2021
5. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood and serious urinary tract infections; 2015. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献